Kura Oncology Stock Earnings Reports

Kura Oncology reported a strong first full-quarter commercial launch for KOMZIFTI (ziftomenib) with $5.8M in net product revenue, ~85 new patient starts and ~160 total prescriptions across ~60 accounts. Management highlights early real-world differentiation versus other menin inhibitors driven by efficacy, predictable safety, simple once-daily dosing and apparent combinability (physician-initiated use with venetoclax/azacitidine and gilteritinib). They reported ~40% of early patients receiving KOMZIFTI in combination and noted early instances of physicians switching patients from other menin inhibitors. Enrollment in the frontline Phase III KOMET-017 program is ahead of plan with strong global site activation; multiple near-term data readouts are expected (EHA: updated 7+3 combination; publication of venetoclax/azacitidine combo; H2: gilteritinib combo and ASCO data for darlifarnib combinations). Financials: Q1 R&D and SG&A rose with launch and program expansion, net loss was $73.3M for the quarter, and cash, equivalents and short-term investments were $580.8M as of March 31, 2026. Management expects collaboration revenue recognition from Kyowa Kirin and states current cash plus anticipated $180M collaboration payments are expected to fund the ziftomenib AML program through the first top-line KOMET-017 Phase III results targeted in 2028. Key investor takeaways: (1) encouraging early commercial traction and physician adoption signals that KOMZIFTI may compete for leadership in the NPM1-mutant AML market; (2) multiple clinical catalysts over the next 12–24 months could materially expand the label and market opportunity if data confirm combinability and durable benefit; (3) financial runway is positioned to reach the initial Phase III readout in 2028.